Associations of Human Leukocyte Antigens (HLA) Class II with Interstitial Lung Disease (ILD) in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs). A Prospective Study in Sequential Patients with SARD-ILD

被引：0
|
作者：
Panagopoulos, Panagiotis [1 ]
Chatzis, Loukas [2 ]
Kitsiou, Vasiliki [3 ]
Tarassi, Katerina [3 ]
Chatzinikita, Eirini [4 ]
Malagari, Katerina [5 ]
Vassilakopoulos, Theodoros [4 ]
Tsirogianni, Alexandra [3 ]
Goules, Andreas [6 ]
Tzioufas, Athanasios [7 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Pathophysiol, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Athens Sch Med, Pathophysiol Dept, Athens, Greece
[3] Evangelismos Gen Hosp, Immunol & Histocompatibil Dept, Athens, Greece
[4] Natl & Kapodistrian Univ Athens, Sch Med, Dept Physiol, Athens, Greece
[5] Natl & Kapodistrian Univ Athens, Sch Med, Dept Radiol 2, Athens, Greece
[6] Gen Hosp Laiko Athens, Athens, Greece
[7] Laiko Hosp, Athens, Greece
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1424
引用
收藏
页码：2891 / 2892
页数：2
相关论文
共 36 条
  • [21] Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
    Bonella, F.
    Humphries, S.
    Hachulla, E.
    Hamblin, M.
    Ogura, T.
    Wormanns, D.
    Ittrich, C.
    Risse, F.
    Alves, M.
    Gahlemann, M.
    Lynch, D. A.
    PNEUMOLOGIE, 2021, 75 : S24 - S25
  • [22] Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
    Humphries, Stephen
    Hachulla, Eric
    Hamblin, Mark
    Ogura, Takashi
    Wormanns, Dag
    Ittrich, Carina
    Risse, Frank
    Alves, Margarida
    Gahlemann, Martina
    Lynch, David
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [23] DESIGN OF A PROSPECTIVE MULTI-NATIONAL CROSS-SECTIONAL STUDY ON SCREENING FOR INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) GUIDED BY RISK FACTORS
    Sparks, J.
    Dieude, P.
    Hoffmann-Vold, A. M.
    Burmester, G. R.
    Walsh, S.
    Kreuter, M.
    Stock, C.
    Sambevski, S.
    Alves, M.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1316 - 1317
  • [24] Correlations Between Changes in FVC and Imaging Parameters in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Sub-Study of the SENSCIS Trial
    Humphries, S. M.
    Khanna, D.
    Takeuchi, T.
    Hamblin, M.
    Wormanns, D.
    Ittrich, C.
    Risse, F.
    Stowasser, S.
    Gahlemann, M.
    Lynch, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [25] Drug-Drug Interaction Study of Nintedanib (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
    Vonk, Madelon
    Avis, Mandy
    Marzin, Kristell
    Mack, Salome
    Wind, Sven
    Gahlemann, Martina
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [26] ULTRASOUND (US) ASSESSMENT OF SKIN THICKNESS IN SYSTEMIC SCLEROSIS (SSC) PATIENTS TREATED WITH IV CYCLOPHOSPHAMIDE (CYC) FOR INTERSTITIAL LUNG DISEASE (ILD): A PILOT STUDY TO ASSESS SENSITIVITY TO CHANGE
    Ottewell, Lesley
    Walker, Karen
    Griffiths, Bridget
    RHEUMATOLOGY, 2010, 49 : I111 - I112
  • [27] Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study
    Bonella, Francesco
    Carmen, Maria
    Sanchez, Vegas
    Millan, Paloma
    Gottstein, Eva
    Sanchez Pernaute, Olga
    Castillo, Diego
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [28] Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and the Potential Future Role of Anti-fibrotics[asterisk] in a Treatment Paradigm for SSc-ILD: A Delphi Consensus Study
    Rahaghi, F. F.
    Strek, M. E.
    Southern, B. D.
    Saggar, R.
    Hsu, V.
    Mayes, M. D.
    Silver, R. M.
    Steen, V.
    Domsic, R. T.
    Rosas, I. O.
    Kaner, R. J.
    Bhatt, N. Y.
    Flaherty, K. R.
    Gupta, N.
    Martinez, F. J.
    Morrow, L. E.
    Patel, N.
    Shlobin, O. A.
    Bernstein, E. J.
    Castelino, F. V.
    Chung, L.
    Kahaleh, B.
    Moua, T.
    Volkmann, E. R.
    Khanna, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [29] BRONCHOALVEOLAR LAVAGE (BAL) FLUID AND SERUM FROM PATIENTS WITH SYSTEMIC SCLEROSIS WITH INTERSTITIAL LUNG DISEASE (SSC-ILD) PROMOTE A PRO-INFLAMMATORY GENE SIGNATURE IN HUMAN PRIMARY LUNG FIBROBLASTS
    Al-Adwi, Y.
    Westra, J.
    Stel, A. J.
    Van Goor, H.
    Mulder, D. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1193 - 1194
  • [30] Efficacy and Safety of Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease (SSc-ILD): Results from the Phase IIb RISE-SSc Study
    Distler, O.
    Allanore, Y.
    Denton, C.
    Kuwana, M.
    Matucci-Cerinic, M.
    Pope, J. E.
    Pena, J. de Oliveira
    Laapas, K.
    Yao, Z.
    Behmenburg, F.
    Hemmrich, M.
    Khanna, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
1234